QSYMIA Drug Patent Profile

When do Qsymia patents expire, and what generic alternatives are available?

Qsymia is a drug marketed by Vivus Llc and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has forty patent family members in seventeen countries.

The generic ingredient in QSYMIA is phentermine hydrochloride; topiramate. There are seventeen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride; topiramate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qsymia

A generic version of QSYMIA was approved as phentermine hydrochloride; topiramate by ACTAVIS LABS FL INC on June 25^th, 2024.

Summary for QSYMIA

International Patents:	40
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	20
Drug Prices:	Drug price information for QSYMIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QSYMIA
What excipients (inactive ingredients) are in QSYMIA?	QSYMIA excipients list
DailyMed Link:	QSYMIA at DailyMed

See drug prices for QSYMIA

Recent Clinical Trials for QSYMIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Minnesota	PHASE3
Mayo Clinic	PHASE4
University of Toronto	PHASE4

See all QSYMIA clinical trials

Pharmacology for QSYMIA

Drug Class	Sympathomimetic Amine Anorectic
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers
Physiological Effect	Appetite Suppression Decreased Central Nervous System Disorganized Electrical Activity Increased Sympathetic Activity

Paragraph IV (Patent) Challenges for QSYMIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QSYMIA	Extended-release Capsules	phentermine hydrochloride; topiramate	3.75 mg/23 mg 7.5 mg/46 mg 11.25 mg/69 mg 15 mg/92 mg	022580	1	2013-07-18

US Patents and Regulatory Information for QSYMIA

QSYMIA is protected by six US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-004	Jul 17, 2012	AB	RX	Yes	Yes
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-001	Jul 17, 2012	AB	RX	Yes	No
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-003	Jul 17, 2012	AB	RX	Yes	No			Y

Expired US Patents for QSYMIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-003	Jul 17, 2012
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-004	Jul 17, 2012
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-001	Jul 17, 2012

International Patents for QSYMIA

When does loss-of-exclusivity occur for QSYMIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Cyprus

Denmark

European Patent Office

Hong Kong

Israel

Japan

Mexico

Portugal

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QSYMIA around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	1285	Anticonvulsant sulfamate derivatives useful in treating obesity.
African Regional IP Organization (ARIPO)	9801429
Austria	224189

Supplementary Protection Certificates for QSYMIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2317997	CA 2021 00049	Denmark		PRODUCT NAME: PHENTERMIN OG TOPIRAMAT; NAT. REG. NO/DATE: 63166, 63167, 63168, 63169 20210705; FIRST REG. NO/DATE: IS IS/1/21/018/01-04 20210212
2317997	CR 2021 00049	Denmark		PRODUCT NAME: PHENTERMIN OG TOPIRAMAT; NAT. REG. NO/DATE: 63166, 63167, 63168, 63169 20210705; FIRST REG. NO/DATE: IS IS/1/21/018/01-04 20210212
2317997	2190050-1	Sweden		PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212

QSYMIA (phentermine/topiramate) market dynamics and financial trajectory: exclusivity, competition, pricing, and revenue sensitivity

Last updated: July 21, 2026

Qsymia (phentermine/topiramate; VIVUS/unsupported branded history now under Adapt Pharma) has operated in a crowded obesity market where GLP-1 and dual agonists have compressed demand economics. The branded revenue base has stayed dependent on payer coverage, dose mix, and channel strategy, while generic and manufactured-combination entry risk has governed pricing power. The financial trajectory is best read through a) FDA label limitations and REMS/coverage patterns, b) commercial loss from GLP-1 competitors, and c) the remaining patent and exclusivity envelope that reduces generic/authorized-try pressure.

---

What is Qsymia’s market position in anti-obesity drugs vs GLP-1 competitors?

Qsymia is a long-term weight management medicine built on a combination of phentermine (sympathomimetic appetite suppressant) and topiramate (satiety-promoting effects). Commercially, it historically competed for payor and prescriber share against:

• Orlistat
• Phentermine/topiramate generics and compounding pressures (where available and permitted)
• Higher-efficacy incretin therapies (GLP-1 receptor agonists such as semaglutide, and dual agonists such as tirzepatide)
• Anti-obesity pharmacotherapies across multiple classes (agents with different efficacy and tolerability profiles)

How did class competition change demand dynamics?

The obesity category’s demand curve has shifted toward products with higher average weight-loss outcomes and broader clinical guideline alignment. Qsymia’s relative performance on absolute weight reduction and payer preference has weakened as payers increasingly tighten step edits in favor of GLP-1/dual agonists.

Net effect on Qsymia:

• Higher marketing burden to defend formulary position
• More variability in prescription volume by coverage policy
• Lower pricing power as alternative products become preferred under managed-care formularies

---

How strong is Qsymia’s patent estate and exclusivity timeline?

Qsymia’s ability to sustain premium pricing historically has been tied to branded protection and to preventing combination-generic erosion. The critical business question for launch risk is whether generic or AB-rated alternatives exist for the exact combination and dose forms.

What is the key FDA exclusivity for Qsymia?

Qsymia is an approved combination product. The relevant market-barrier framework is:

• New chemical entity/exclusivity (if applicable at approval)
• Patent coverage for combination composition, dosing regimens, and formulations
• Orange Book listing breadth and remaining life by jurisdiction

What is the generic entry risk for Qsymia?

From a market-dynamics standpoint, the generic threat line is usually determined by:

• Whether the exact strength combination is listed for generic approval
• The presence and strength of formulation, method-of-use, and combination-specific patents
• Litigation outcomes (if any) controlling Paragraph IV entry timing

Business impact:

• If generics are available or approvals are already issued, Qsymia’s revenue trajectory becomes a pricing and volume tug-of-war rather than a growth story.
• If patent and exclusivity still constrain generic substitution, Qsymia behaves more like a durable brand in a fragmented obesity market.

(Patent and Orange Book-specific dates are not reliably retrievable in this session from a complete dataset, so the analysis below does not assert specific expiration dates.)

---

What is the Orange Book status of Qsymia and which products can be substituted?

Qsymia’s competitive and licensing risk maps to the Orange Book entry list for:

• Drug substance: phentermine/topiramate
• Dosage forms: extended-release capsule strengths (where listed)
• Listed patents: composition, method of use, formulation, and manufacturing/packaging

How many Orange Book listings typically drive Qsymia competition?

In obesity combination products, patent estates often include:

• Drug substance claims covering the combination
• Method-of-use claims for weight loss endpoints and clinically-defined responder criteria
• Formulation and release-profile claims (where ER is central)

Market implication: the more narrow the remaining enforceable claims, the faster pricing shifts once substitution is allowed. If key claims are invalidated or design-aroundable, payers can pivot to lower-cost options even before full erosion of branded product.

(Orange Book listing counts and exact claim expirations are not asserted here because the full listing set is not present in the provided materials.)

---

What patent litigation and Paragraph IV challenges affect Qsymia’s revenue?

For combination anti-obesity products, Paragraph IV litigation can move revenues in two ways:

• A delayed generic entry can preserve price and volume for a defined window
• An adverse outcome accelerates volume loss and compounding substitution

What settlement dynamics matter for Qsymia commercial pricing?

Settlements that include:

• “Carve-outs” by dose/strength
• Trigger dates tied to launch milestones
• License terms that cap price or limit labeling can control the pace at which branded demand decays.

Revenue sensitivity to litigation:

• If launch timing is imminent, prescribers and payers increase switching even before launch.
• Once generics are available, branded net price compresses quickly, typically outpacing volume declines as payers demand rebates and price parity.

(No specific Qsymia litigation docket or settlement terms are asserted because case identifiers and outcomes are not available in the supplied context.)

---

How have pricing, net-to-gross, and payer mix influenced Qsymia financial trajectory?

For chronic obesity pharmacotherapy, brand economics hinge on payer behavior more than pure patient demand.

Key drivers of Qsymia net revenue

• Coverage status and step therapy requirements
• Prior authorization burden
• Commercial and Medicare Part D formulary tiers
• Net-to-gross pressure from rebate negotiations
• Dose mix (maintenance vs titration patterns) that drives pill consumption and adherence

Managed care shifts

GLP-1/dual agonists with strong outcomes have led many plans to:

• Favor first-line incretin therapy
• Limit non-incretin options to failure criteria or lower tiers
• Expand utilization management for duplicate therapies

Implication for Qsymia: even if patient willingness remains, reimbursed demand becomes the binding constraint.

---

Which competitors most affected Qsymia’s sales curve?

Qsymia faces competition from two directions:

1. Within-label weight management from older and newer agents
2. Payer-favored incretin and dual agonist products with stronger average weight loss

Direct class competition map

• GLP-1 receptor agonists (semaglutide and related class members)
• Dual agonists (tirzepatide and related agents)
• Older sympathomimetic and GI-fat absorption therapies
• Other anti-obesity combination regimens, depending on formulary position

What happens to Qsymia demand when GLP-1 access improves?

When plans expand access or reduce prior authorization:

• Qsymia’s incremental patient starts tend to fall first
• Existing users may switch at next renewal
• Brand net revenue becomes increasingly dependent on remaining pockets of coverage

---

Is Qsymia’s revenue trajectory more impacted by volume decline or net price compression?

In branded obesity drugs facing new high-efficacy entrants, both effects can occur, but volume often falls faster when coverage policies tighten.

Volume compression mechanism

• Fewer new starts under PA and step edits
• Lower persistence when therapy is switched for better outcomes
• Increased use of alternative agents that satisfy plan-defined “preferred” criteria

Net price compression mechanism

• Higher rebate requirements to maintain formulary position
• Price parity pressure once lower-cost alternatives exist
• Contract renegotiations that shift gross-to-net downward

Business reading: Qsymia financial trajectory typically behaves like a mature brand under competitive displacement, where incremental growth is limited and declines accelerate with coverage tightening.

---

What are Qsymia’s growth levers and what limited them?

What growth levers mattered historically

• Label-based expansion and adherence support
• Dose-optimization to maintain responder rates
• Pharmacy channel execution and REMS-like prescriber safeguards where applicable
• Managed-care contracting targeted at “chronic obesity” cohorts

What limited Qsymia’s upside

• High comparators from GLP-1/dual agonists
• Contraindications and tolerability considerations that limit long-term continuation for some patients
• Payer preference shifts that reduce start rates
• Generic and substitution pressures for combination products once legal and regulatory barriers loosen

---

How does Qsymia manufacturing and supply chain affect financial stability?

Drug supply stability matters more for brands under strong competition because lost fills translate into:

• Faster formulary switching by plans
• Prescriber stickiness erosion
• Contract penalties and customer service costs

For Qsymia, manufacturing complexity is moderate given oral combination ER dosing. Financial stability depends on maintaining:

• ER batch consistency to prevent quality holds
• Conversion and packaging throughput for multiple strengths
• Forecast accuracy in a volatile demand environment

---

What licensing or commercialization transitions have influenced Qsymia financial performance?

Qsymia’s branded commercialization has changed hands over time, influencing:

• Salesforce investment intensity
• Contract strategy with payers and specialty pharmacies
• Market-access aggressiveness versus cost containment

Commercial implication: ownership transitions often change the speed of execution on formulary wins and the willingness to defend net price via rebates.

---

What generic entry scenarios could erode Qsymia revenue?

Generic erosion scenarios in combination ER obesity products typically include:

• Launch of AB-rated generics at one or multiple strengths
• “Design-around” formulations that preserve certain release characteristics but clear regulatory thresholds
• Authorized generics via license arrangements

How could payer substitution accelerate after launch?

• Automatic formulary tier downgrades
• Switch incentives at pharmacy point of sale
• Increased prior authorization for the brand to protect plan net costs

Revenue sensitivity: brand sales can drop rapidly after a sustained availability of generics because payers can enforce substitution without waiting for patient outcomes.

---

Key takeaways on Qsymia market dynamics and financial trajectory

• Qsymia competes in a structurally shifting obesity market where GLP-1/dual agonists have changed payer preference and reduced incremental share growth.
• Branded revenue trajectory is governed more by payer coverage mechanics and net price than by broad underlying patient demand.
• The speed of branded erosion depends on the Orange Book patent and generic substitution landscape, including litigation outcomes and any strength-specific carve-outs.
• Under competitive displacement, Qsymia behaves like a mature brand: adherence and dose mix determine remaining volume while rebate pressure and tier placement determine net price.

---

FAQs

1) What are the main payers’ utilization management levers that affect Qsymia scripts?
Prior authorization criteria, step therapy requirements, formulary tiering, and quantity limits tied to clinically defined responder metrics.

2) Does Qsymia’s extended-release dosing impact generic substitution risk?
It can, because formulation and release-profile claims can protect specific manufacturing and product characteristics if enforceable.

3) How do GLP-1 access expansions typically change non-incretin anti-obesity drug sales?
They usually reduce new starts first through PA denials and shift existing users at renewal or when prior authorization is reevaluated.

4) What settlement terms most affect the timing of Qsymia generic entry?
Trigger dates, strength carve-outs, and covenants that limit design-around or labeling before full approval to launch.

5) What financial metrics are most predictive of Qsymia future trajectory?
Net-to-gross trend, formulary coverage changes by payer segment, dose mix changes, and persistence/switch rates after incretin uptake.

---

References

1. FDA. Drugs@FDA: Qsymia (phentermine and topiramate) label and approval history. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Qsymia listings). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
3. FDA. Drug Development and Drug Interactions: labeling and safety information for phentermine/topiramate. U.S. Food and Drug Administration. https://www.fda.gov/

DrugChatter Q&A for QSYMIA

Qsymia obesity drug company evaluation?
Qsymia weight loss drug evaluation efficacy safety company manufacturer?
Qsymia generic availability?
Generic version of qsymia?
Is there a generic qsymia?